Hepatocellular carcinoma in HIV positive patients

G. Nunnari, M. Berretta, M. R. Pinzone, M. Di Rosa, S. Berretta, G. Cunsolo, M. Malaguarnera, S. Cosentino, P. De Paoli, J. M. Schnell, B. Cacopardo

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Highly active antiretroviral therapy (HAART) has dramatically changed the natural history of HIV-1-Infected patients leading to increased survival and a better quality of life. Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are common among HIV-1-Infected subjects and represent the most important risk factors for hepatocellular carcinoma (HCC). Whether HIV plays a direct role in hepatocellular carcinoma (HCC) pathogenesis remains to be established. HCC clinical course depends on stage of cancer disease, performance status and comorbidities. Therapeutic options include liver transplantation, local antiblastic chemotherapy and biological drugs. In the HIV setting few data are available about treatment options. The increased longevity of patients with HIV imposes new strategies for prevention and therapeutic management of patients. The aim of this article is to provide an up-To-Date review of HIV-Related HCC in the HAART era.

Original languageEnglish
Pages (from-to)1257-1270
Number of pages14
JournalEuropean Review for Medical and Pharmacological Sciences
Volume16
Issue number9
Publication statusPublished - Sep 2012

Fingerprint

Hepatocellular Carcinoma
HIV
Highly Active Antiretroviral Therapy
HIV-1
Virus Diseases
Natural History
Hepatitis B virus
Hepacivirus
Liver Transplantation
Comorbidity
Therapeutics
Quality of Life
Drug Therapy
Survival
Pharmaceutical Preparations
Neoplasms

Keywords

  • Co-Infection
  • HAART
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular carcinoma
  • HIV
  • Liver transplant

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Nunnari, G., Berretta, M., Pinzone, M. R., Di Rosa, M., Berretta, S., Cunsolo, G., ... Cacopardo, B. (2012). Hepatocellular carcinoma in HIV positive patients. European Review for Medical and Pharmacological Sciences, 16(9), 1257-1270.

Hepatocellular carcinoma in HIV positive patients. / Nunnari, G.; Berretta, M.; Pinzone, M. R.; Di Rosa, M.; Berretta, S.; Cunsolo, G.; Malaguarnera, M.; Cosentino, S.; De Paoli, P.; Schnell, J. M.; Cacopardo, B.

In: European Review for Medical and Pharmacological Sciences, Vol. 16, No. 9, 09.2012, p. 1257-1270.

Research output: Contribution to journalArticle

Nunnari, G, Berretta, M, Pinzone, MR, Di Rosa, M, Berretta, S, Cunsolo, G, Malaguarnera, M, Cosentino, S, De Paoli, P, Schnell, JM & Cacopardo, B 2012, 'Hepatocellular carcinoma in HIV positive patients', European Review for Medical and Pharmacological Sciences, vol. 16, no. 9, pp. 1257-1270.
Nunnari G, Berretta M, Pinzone MR, Di Rosa M, Berretta S, Cunsolo G et al. Hepatocellular carcinoma in HIV positive patients. European Review for Medical and Pharmacological Sciences. 2012 Sep;16(9):1257-1270.
Nunnari, G. ; Berretta, M. ; Pinzone, M. R. ; Di Rosa, M. ; Berretta, S. ; Cunsolo, G. ; Malaguarnera, M. ; Cosentino, S. ; De Paoli, P. ; Schnell, J. M. ; Cacopardo, B. / Hepatocellular carcinoma in HIV positive patients. In: European Review for Medical and Pharmacological Sciences. 2012 ; Vol. 16, No. 9. pp. 1257-1270.
@article{2c98dbc56f7c48fd9169ed189d18b3c4,
title = "Hepatocellular carcinoma in HIV positive patients",
abstract = "Highly active antiretroviral therapy (HAART) has dramatically changed the natural history of HIV-1-Infected patients leading to increased survival and a better quality of life. Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are common among HIV-1-Infected subjects and represent the most important risk factors for hepatocellular carcinoma (HCC). Whether HIV plays a direct role in hepatocellular carcinoma (HCC) pathogenesis remains to be established. HCC clinical course depends on stage of cancer disease, performance status and comorbidities. Therapeutic options include liver transplantation, local antiblastic chemotherapy and biological drugs. In the HIV setting few data are available about treatment options. The increased longevity of patients with HIV imposes new strategies for prevention and therapeutic management of patients. The aim of this article is to provide an up-To-Date review of HIV-Related HCC in the HAART era.",
keywords = "Co-Infection, HAART, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, HIV, Liver transplant",
author = "G. Nunnari and M. Berretta and Pinzone, {M. R.} and {Di Rosa}, M. and S. Berretta and G. Cunsolo and M. Malaguarnera and S. Cosentino and {De Paoli}, P. and Schnell, {J. M.} and B. Cacopardo",
year = "2012",
month = "9",
language = "English",
volume = "16",
pages = "1257--1270",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "9",

}

TY - JOUR

T1 - Hepatocellular carcinoma in HIV positive patients

AU - Nunnari, G.

AU - Berretta, M.

AU - Pinzone, M. R.

AU - Di Rosa, M.

AU - Berretta, S.

AU - Cunsolo, G.

AU - Malaguarnera, M.

AU - Cosentino, S.

AU - De Paoli, P.

AU - Schnell, J. M.

AU - Cacopardo, B.

PY - 2012/9

Y1 - 2012/9

N2 - Highly active antiretroviral therapy (HAART) has dramatically changed the natural history of HIV-1-Infected patients leading to increased survival and a better quality of life. Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are common among HIV-1-Infected subjects and represent the most important risk factors for hepatocellular carcinoma (HCC). Whether HIV plays a direct role in hepatocellular carcinoma (HCC) pathogenesis remains to be established. HCC clinical course depends on stage of cancer disease, performance status and comorbidities. Therapeutic options include liver transplantation, local antiblastic chemotherapy and biological drugs. In the HIV setting few data are available about treatment options. The increased longevity of patients with HIV imposes new strategies for prevention and therapeutic management of patients. The aim of this article is to provide an up-To-Date review of HIV-Related HCC in the HAART era.

AB - Highly active antiretroviral therapy (HAART) has dramatically changed the natural history of HIV-1-Infected patients leading to increased survival and a better quality of life. Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are common among HIV-1-Infected subjects and represent the most important risk factors for hepatocellular carcinoma (HCC). Whether HIV plays a direct role in hepatocellular carcinoma (HCC) pathogenesis remains to be established. HCC clinical course depends on stage of cancer disease, performance status and comorbidities. Therapeutic options include liver transplantation, local antiblastic chemotherapy and biological drugs. In the HIV setting few data are available about treatment options. The increased longevity of patients with HIV imposes new strategies for prevention and therapeutic management of patients. The aim of this article is to provide an up-To-Date review of HIV-Related HCC in the HAART era.

KW - Co-Infection

KW - HAART

KW - Hepatitis B

KW - Hepatitis C

KW - Hepatocellular carcinoma

KW - HIV

KW - Liver transplant

UR - http://www.scopus.com/inward/record.url?scp=84867972791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867972791&partnerID=8YFLogxK

M3 - Article

C2 - 23047511

AN - SCOPUS:84867972791

VL - 16

SP - 1257

EP - 1270

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 9

ER -